Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Opinion Editor's Corner ACC 2016

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Shelley Wood

April 13, 2016

News Conference News ACC 2016

More Evidence That Morphine Hampers Effects of Antiplatelet Therapy in STEMI

Todd Neale

April 02, 2016

News Conference News ACC 2015

BEST: Due to Less TVR, CABG Still Favored Over PCI in Patients with Multivessel Disease

L.A. McKeown

March 16, 2015

News Conference News ACC 2015

Long-Term DAPT with Ticagrelor Reduces Ischemic Risk, Ups Bleeding in MI Patients

Todd Neale

March 14, 2015

News Conference News ACC 2014

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Yael L. Maxwell

April 03, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Conference News ACC 2014

CHOICE Trial, TVT Registry Shed Light on Evolving TAVR Outcomes, Risks

L.A. McKeown

March 31, 2014

News Conference News ACC 2013

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

L.A. McKeown

March 14, 2013

News Conference News ACC 2013

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Jason Kahn

March 11, 2013

News Conference News ACC 2013

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

Yael L. Maxwell

March 09, 2013

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Conference News ACC 2012

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

L.A. McKeown

March 26, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Conference News ACC 2012

EXOME: New Genetic Sequencing Zeroes in on Clopidogrel Response Variants

March 25, 2012

News Conference News ACC 2012

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

L.A. McKeown

March 25, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

News Conference News ACC 2012

Prasugrel Effective in Stable Patients With Poor Response to Clopidogrel

Jason Kahn

March 24, 2012

News Conference News ACC 2012

New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding

L.A. McKeown

March 24, 2012

News Conference News ACC 2012

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

March 24, 2012

Advertisement

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

More Evidence That Morphine Hampers Effects of Antiplatelet Therapy in STEMI

BEST: Due to Less TVR, CABG Still Favored Over PCI in Patients with Multivessel Disease

Long-Term DAPT with Ticagrelor Reduces Ischemic Risk, Ups Bleeding in MI Patients

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

CHOICE Trial, TVT Registry Shed Light on Evolving TAVR Outcomes, Risks

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

EXOME: New Genetic Sequencing Zeroes in on Clopidogrel Response Variants

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Prasugrel Effective in Stable Patients With Poor Response to Clopidogrel

New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content